DAX25.147 +0,1%Est506.280 +0,2%MSCI World4.343 -0,1%Top 10 Crypto8,3300 +0,4%Nas26.107 +0,9%Bitcoin56.820 -0,1%Euro1,1435 +0,1%Öl85,19 +0,5%Gold4.031 -0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SpaceX A42D4F SAP 716460 NVIDIA 918422 IBM 851399 Infineon 623100 Siemens Energy ENER6Y EVOTEC 566480 Deutsche Telekom 555750 Microsoft 870747 Micron Technology 869020 Lufthansa 823212 Volkswagen (VW) vz. 766403 BYD A0M4W9 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schwächer erwartet -- Asiens Börsen mehrheitlich stärker - KOSPI zieht an -- NEL mit höherem Verlust, aber kräftigem Plus beim Auftragseingang -- Schaeffler, ASML, Rio Tinto im Fokus
Top News
ASML-Aktie zieht an: Konzern rechnet 2026 mit noch besseren Geschäften ASML-Aktie zieht an: Konzern rechnet 2026 mit noch besseren Geschäften
Bilanzen & Termine: Tesla, NVIDIA, Apple, Amazon & Co. - Ergebnisse der Tech-Riesen in der aktuellen Saison Bilanzen & Termine: Tesla, NVIDIA, Apple, Amazon & Co. - Ergebnisse der Tech-Riesen in der aktuellen Saison
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Iovance Biotherapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
3,41 EUR -0,06 EUR -1,59 %
STU
3,96 USD +0,02 USD +0,51 %
nachbörslich
BTT
finanzen.net zero
Iovance Biotherapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,58 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2DT49

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4622601007

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIOVA

Iovance Biotherapeutics Aktien News

DatumMeistgelesen
MotleyFoolHeartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
MotleyFoolAmgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
ZacksIovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates
Wer­bungIovance Biotherapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
ZacksIovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ZacksIovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
BenzingaWhat's Going On With Iovance Biotherapeutics Stock On Friday?
MotleyFoolIovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036
BenzingaA Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts
BenzingaIovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy
ZacksIovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
MotleyFoolDown 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
ZacksIovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates
MotleyFoolBetter Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
MotleyFoolIs Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?
MotleyFoolWhy Iovance Biotherapeutics Stock Got Mashed on Monday
MotleyFoolWhy Iovance Biotherapeutics Stock Was Climbing Today
MotleyFoolWhy Iovance Biotherapeutics Stock Plummeted Today
BenzingaWhat 7 Analyst Ratings Have To Say About Iovance Biotherapeutics
BenzingaIovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening
ZacksIovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
MotleyFoolIs Iovance Biotherapeutics Stock Due for a Big Rally?
PR NewswireLost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireIOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireIovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireIOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA

Iovance Biotherapeutics News

Iovance Biotherapeutics News: auf dieser Seite finden Sie alle Iovance Biotherapeutics News und Nachrichten zur Iovance Biotherapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Iovance Biotherapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Iovance Biotherapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.